A phase II study (SAFIR PI3K) is underway in patients with PIK3CA-mutated advanced breast cancer which compares Alpelisib and ER inhibitor (Fulvestrant) versus chemotherapy in these patients. Here, PIK3CA is linked to breast carcinoma.